Balance Sheet Insights: AbCellera Biologics Inc (ABCL)’s Debt-to-Equity and Long-Term Debt/Eq Ratios

In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

In the latest session, AbCellera Biologics Inc (NASDAQ: ABCL) closed at $2.48 down -4.25% from its previous closing price of $2.59. In other words, the price has decreased by -$4.25 from its previous closing price. On the day, 1.58 million shares were traded. ABCL stock price reached its highest trading level at $2.62 during the session, while it also had its lowest trading level at $2.48.

Ratios:

For a deeper understanding of AbCellera Biologics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.96 and its Current Ratio is at 10.96. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.06.

On February 22, 2024, The Benchmark Company Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $9.

On December 05, 2023, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $6.KeyBanc Capital Markets initiated its Overweight rating on December 05, 2023, with a $6 target price.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABCL now has a Market Capitalization of 730771648 and an Enterprise Value of 132468520. For the stock, the TTM Price-to-Sale (P/S) ratio is 22.10 while its Price-to-Book (P/B) ratio in mrq is 0.66. Its current Enterprise Value per Revenue stands at 4.008 whereas that against EBITDA is -0.617.

Stock Price History:

Over the past 52 weeks, ABCL has reached a high of $6.05, while it has fallen to a 52-week low of $2.34. The 50-Day Moving Average of the stock is -11.22%, while the 200-Day Moving Average is calculated to be -38.57%.

Shares Statistics:

For the past three months, ABCL has traded an average of 1.89M shares per day and 2300420 over the past ten days. A total of 290.82M shares are outstanding, with a floating share count of 206.64M. Insiders hold about 29.87% of the company’s shares, while institutions hold 36.27% stake in the company. Shares short for ABCL as of 1724976000 were 17551585 with a Short Ratio of 9.27, compared to 1722384000 on 17415579. Therefore, it implies a Short% of Shares Outstanding of 17551585 and a Short% of Float of 7.739999999999999.

Most Popular